Interestingly, the subgroup analysis in this meta-analysis suggested that the mortality benefit of SGLT2 inhibitors may be more pronounced in patients with breast cancer and lung cancer compared to those with hepatoma. This evidence concerns the gene SLC5A2 and breast carcinoma.